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A9-Tetrahydrocannabinol (THC) is the major psychoactive component of marijuana. Marijuana and its cannabinoid derivatives induce a wide spectrum of effects including analgesia, antiemetic, anticonvulsion, attenuation of intraocular pressure in glaucoma, antiinflammation, and immunosuppression (1) . One of the major concerns of habitual marijuana smoking or exposure to cannabinoid derivatives is their reported adverse effects on reproductive functions, including fetal loss, pregnancy failure, retarded embryonic development, and reduced fertilizing capacity of sperm (reviewed in refs. [2] [3] [4] [5] . The mechanisms by which these effects of cannabinoids are mediated are poorly defined. Furthermore, controversies still prevail surrounding the "estrogenic-antiestrogenic" effects of cannabinoids in uterine biology (2, 6, 7) and their interactions with uterine estrogen receptors (8, 9) . Previous identification of guanine nucleotide-binding protein (G-protein)-coupled cannabinoid receptors together with the recent cloning of these cannabinoid receptors in the brain (CB1-R) and spleen (CB2-R) (10) (11) (12) have begun to provide evidence that many of the central and peripheral effects of cannabinoids are likely to be mediated via these receptors. Furthermore, the identification of a putative endogenous cannabinoid ligand, anandamide (arachidonylethanolamide), in the brain suggests that canna-
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binoid ligand-receptor signaling may be normally operative in the central nervous system (13, 14) , although the physiological significance of this signaling pathway is yet to be defined.
The CB2-R gene has been shown to be expressed only in the spleen, while the CB1-R gene is primarily expressed in the brain (11, 12) . The other tissues that have been shown to express CB1-R mRNA are the testis, spleen, and peripheral blood leukocytes (15) (16) (17) . The expression of cannabinoid receptors in the spleen and leukocyte has been associated with the antiinflammatory and immunosuppressive roles of cannabinoids (16, 17) , while the observation of reduced fertilizing capacity of sperm exposed to cannabinoid ligands is consistent with the detection of CB1-R mRNA in the testis and cannabinoid binding sites in the sperm (4, 5, 15) . On the other hand, the effects and mode of action of cannabinoids in uterine biology and pregnancy remain largely undefined and controversial in spite of the numerous reports published in this field during the last two decades (2, 3) . In the present investigation, we sought to examine whether functional cannabinoid receptors are expressed in the uterus and whether this organ has the capacity to synthesize anandamide. We further examined whether THC can influence uterine functions at the molecular level by examining the expression of the gene encoding lactoferrin (LF), an estrogen-responsive gene in the mouse uterus.
MATERIALS AND METHODS
Northern Blot Hybridization of CB1-R mRNA. Uteri from CD-1 mice on days 1, 4, and 7 of pregnancy (day 1 = vaginal plug) were used in this study to determine whether the changing hormonal status of the mother and corresponding changes in uterine physiology alter the expression of CB1-R mRNA (18). Total RNA from the mouse brain or uteri was extracted by using a modified guanidine thiocyanate procedure (19) . Poly(A)+ RNA was isolated by oligo(dT)-cellulose column chromatography (19) . A 1.17-kb fragment encoding 97-1271 nucleotides of the rat CB1-R cDNA clone SKR6 was subcloned into a pGEM vector (11) . A cDNA clone of human fibroblast cytoplasmic p-actin was subcloned into a pGEM vector (20 (11) and 5'-CCTGTTGAAGATCGGC-AGCG-3' (sense) and 5'-GGTAGGAGATCAACGCCG-AG-3' (antisense) for the CB2-R transcript (12). The internal oligonucleotides were used for Southern hybridization of the amplified products for CB1-R and CB2-R, respectively. The 3-actin sense and antisense primers designed from the mouse p-actin cDNA were 5'-GTGGGCCG-CTCTAGGCACCAA-3' and 5'-CTCTTTGATGTCACGCA-CGATTTC-3', respectively (21). An internal oligonucleotide, 5'-CCACGGGCATTGTGATGGAC-3', was used for Southern analysis. RNA from brain, spleen, or uterus was isolated (19, 22) . Total RNA (1 ,tg) from each sample was reversetranscribed by using specific antisense primers. A portion (one-third) of the RT products were subjected to PCR amplification by using the sense and antisense primers in the buffer as described by us (22) . PCR cycle parameters were as follows:
94°C for 4 min, 55°C for 1.5 min, and 72°C for 2.5 min for the first cycle followed by 94°C for 1 min, 55°C for 1.5 min, and 72°C for 2.5 min for a total of 35 cycles. One-tenth of the total amplified product was run on 1.5% agarose gels, stained with ethidium bromide, and blotted for Southern hybridization. Experimental and negative control reactions were run simultaneously.
Analysis of Forskolin-Stimulated cAMP Accumulation. Day 1 pregnant uteri were homogenized in 1 ml of 50 mM Tris (pH 7.5) containing 1 mM EGTA and 0.5 mM 3-isobutyl-l-methylxanthene and centrifuged at 2000 x g for 15 min. The supernatant was centrifuged at 100,000 x g for 1 h to obtain membranes. Membranes were resuspended, and an aliquot (350 ,tg of protein) was incubated in 1 ml of the same buffer containing .10 t,M GTP, 1 mM ATP, and 3 mM MgSO4 with or without forskolin (1) (2) (3) (4) (5) at 25°C for 10 min to determine its maximal stimulatory concentration. To assess the effects of agonists, THC (0.1-10 tLM), cannabidiol (CBD; 0.1-10 tM), or anandamide (0.1-10 tLM) was added to the incubation mixture with 5 uLM forskolin. To determine that the effects of the agonists were coupled to the inhibitory G protein (Gi), preincubation with pertussis toxin at 5 ng/ml for 5 min was performed before adding forskolin and THC. Reactions were terminated by boiling (5 min) followed by centrifugation. The cAMP contents of the supernatants were determined by protein-binding assay (23, 24 (PMSF) and were centrifuged at 2000 x g for 15 min. The supernatants (500 j,g of protein) were incubated in 1 ml of 0.1 M Tris-HCl (pH 9.0) containing 1.5 mM PMSF with 1 ,uCi of [5,6,8,9,11,12,14,15-3H(N) (28) . The same blot was reprobed with /3-actin probe, and duplicate gels were stained with acridine orange to ensure RNA integrity and equal loading. After hybridization, the blots were subjected to autoradiography and radioimage quantitation by using the radioanalytic image system (AMBIS).
RESULTS AND DISCUSSION
Analysis of Cannabinoid Receptor mRNAs in the Uterus. As reported (11) , Northern blot analysis detected a 6.0-kb transcript in total brain or pregnant uterine poly(A)+ RNA samples. The abundance of CB1-R mRNA was markedly lower in the uterus. However, a predominant 1.2-kb transcript was detected in the uterus and showed a higher accumulation on days 4 and 7 of pregnancy than that on day 1 (Fig. 1A) . Whether this smaller transcript is the result of alternate splicing or represents a truncated form of the receptor is not known.
RT-PCR also detected CB1-R mRNA in the uterus, confirming the results of Northern blot hybridization (Fig. 1B) . This mRNA was detected in the uterus during early pregnancy and in ovariectomized uteri before and after THC treatment (Fig.   1B) . In contrast, RT-PCR could not detect CB2-R mRNA in the uterus, although this mRNA was detected in the rat or mouse spleen (Fig. 1C) . (Fig. 2A) . Anandamide was more potent than THC in this response. However, as observed for other cannabinoid ligands (29), anandamide was less inhibitory at higher concentrations. These effects of THC or anandamide appear to be specific, since an inactive and nonpsychoactive cannabinoid, CBD, did not alter this response ( Fig. 2A) .
Analysis of WIN 55212-2 Binding Kinetics in the Endometrium. Although 60% of the binding in the endometrium, like that observed in other systems (15), was nonspecific, analysis of the equilibrium binding data (Fig. 2B) (Fig. 3) .
Analysis ofAnandamide Synthesis in the Uterus. The results demonstrate that the uterus, like the brain, has the capacity to synthesize anandamide in the presence of ethanolamine (Fig.  4) (2, 3) suggest that the adverse effects are mediated via interactions with uterine cannabinoid receptors. Furthermore, aberrant uterine expression of the endogenous ligand and/or the receptors may be contributing factors in many incidences of uterine disorders and infertility (2, 3) . Although non-receptor-mediated cannabinoid effects cannot be ruled out (14), our results suggest that a receptor-mediated signaling pathway is present in the mouse uterus to respond to cannabinoid ligands. This study also establishes that cannabinoids can alter the expression of a uterine gene (LF) that is considered to be regulated only by steroid hormones. The present findings are exciting and present us with a new avenue for further exploration of cannabinoid ligand-receptor signaling in uterine biology.
